Gater Deborah, Macauley Donald
Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK.
IDrugs. 2009 Oct;12(10):605-7.
The 238th National Meeting and Exposition of the American Chemical Society, held in Washington DC, included topics covering new compounds and developments in the field of medicinal chemistry. This conference report highlights selected presentations on a novel KV1.5 blocker, a state-dependent CaV2.2 antagonist, therapeutic uses of macrocycles, a novel P2X7 antagonist, developments using the StaR technology platform, the optimization of a neuropeptide S receptor antagonist, and type 1 glycine transport modulators. Investigational drugs discussed include WYE-160020 (Wyeth), Trox-1 (Neuromed Pharmaceuticals Inc), ulimorelin (Tranzyme Pharma Inc), E-32224 (Ensemble Discovery Corp) and PF-03463275 (Pfizer Inc); the discontinued compound AZD-9056 is also highlighted.
在美国华盛顿特区举行的第238届美国化学学会全国会议及展览，涵盖了药物化学领域新化合物和进展等主题。本会议报告重点介绍了关于新型KV1.5阻滞剂、一种电压依赖性CaV2.2拮抗剂、大环化合物的治疗用途、新型P2X7拮抗剂、利用StaR技术平台的进展、神经肽S受体拮抗剂的优化以及1型甘氨酸转运调节剂的部分演讲。讨论的研究药物包括WYE-160020（惠氏公司）、Trox-1（Neuromed制药公司）、乌利莫林（Tranzyme制药公司）、E-32224（Ensemble Discovery公司）和PF-03463275（辉瑞公司）；已停产的化合物AZD-9056也在报告中被重点提及。
